INTRODUCTION
The enzyme-linked immunosorbent assay (ELISA) is the most widely used serological test for detecting antibodies to HIV. [1] [2] [3] [4] Although, the Western blot assay which is often regarded as the gold standard for confirmation of HIV serostatus, indeterminate WB profiles are frequent. [5] Non-specific reactivity on western blot can occur with HIV negative specimens leading to inconclusive or indeterminate results. One of the most common causes of an indeterminate result is because the person tested is in the window period. Besides this, HIV-2 cross reaction, contaminating cellular antigens on viral lysate based blot strips, infection with human T-cell lymphotrophic virus I/II (HTLV I/II), auto antibodies, pregnancy, abnormal bilirubin levels and in-vitro hemolysis have also been suggested as possible causes of indeterminate WB status. [6] [7] [8] Previous studies have indicated that approximately 20-30% of HIV-1 ELISA negative and 4-20% of HIV-1 ELISA positive specimens have indeterminate results by WB assay. [9] [10] [11] [12] The problems with indeterminate results are myriad. The recommended and widely used algorithm for the confirmation of an indeterminate result is to retest the patient after 3 -6 months. [9] But it is infrequent that HIV-1 Western blot indeterminate specimens to become positive in follow-up. [5, 13] The problems in reporting indeterminate result to patients are many some of which include anxiety, psychological distress and the costs associated with retesting. [14] Different regulatory bodies have proposed criteria for the interpretation of the band profiles. The differences in the sensitivity and specificity associated with each criteria may lead to differences in results for the same specimens, [1, 5, 15] and has sometimes even resulted in false positive reports. [16] Herein lies the importance in of the interpretation criteria for accurate diagnosis based on the WB band profiles. [15] It is accepted to confirm western blot indeterminate results with immunofluorescence and Polymerase chain reaction (PCR), [7, 15] which cannot be used by all the laboratories in developing countries. Hence it is mandatory to convey about the best commercially available western blot kit to the scientific population and laboratories in this community, which gives good results. Hence this retrospective study was an attempt to determine the efficiency of kits to rule out nonspecific indeterminate (indeterminate result for a person who is not in the window period) and influence of interpretation criteria for a test, which is considered gold standard worldwide. center; hence it is not aimed on unbiased or eligibility criteria for the patient's results used. As these results are from VCT centre, duplicate patient identification numbers are created to blind the laboratory personal from the patient information. Over the years three different kits were used for the WB. Initially specimens were being run on the NEW LAV BLOT I, Biorad, France (3, Boulevard Raymond Poincare, 92430 marnes la coquette, France). Then we have used HIV blot 2.2, Gene labs Diagnostics, Singapore (Genelab Diagnostics pet ltd, 85 Science park, Singapore 118259). And also we are using genetic systems TM HIV-1 Western blot kit, Biorad, USA (Bio-Rad laboratories blood virus division Redmond, WA 98052, U.S.A), a total of 244, 112, and 237 specimens were analyzed in this products respectively. Some specimens have been run on more than one kit. Here we have tested 23 specimens on LAV BLOT I and genetic system kits. Six specimens were run on genetic systems and HIV blot 2.2. All these assay runs were validated by internal quality control provided by the manufacturer. The Western blot results were read primarily with the criteria provided by the manufacturer than they were also analyzed different widely used interpretation criteria: [6, 17] Centre for disease control (CDC)/ Association of State and Territorial Public Health Laboratory Directors (ASTPHLD), World Heath Organization (WHO)/National AIDS Control Organization (NACO, India), American Red Cross (ARC), American Food and Drug Administration (FDA), Consortium for retrovirus serology standardization (CRSS), [18] John Hopkins University (JHU). As we found discrepancies in our results for some of the specimens run on both the LAV BLOT I and the Genetic systems kits, we randomly selected 5 among the 23 specimens and subjected them to a HIV RT-PCR (NeoDin TM HIV type-I RT-PCR Kit, NEODIN Co., Ltd. Korea) for confirmation. We could only run 5 specimens due to limited resources. Follow up data was not available for most of the patients with indeterminate results as we rarely used the same kit during follow up.
METHODS AND MATERIALS

RESULTS
In LAVBLOT I kit there are lots of differences in results when read with different interpretation criteria. To interpret the results WHO criterion was assigned by the manufacturer. There were 158 (64.7) specimens found to be positive out of 244 used in the kit. But on using the various other criteria for interpretation the number of positive results varied from 157 (64.3) to 176 (72.1), while the number of indeterminate varied between 44 (18) and 63 (25.8) . No such variation was present among the negative, which implies that some of the indeterminate specimens would be considered positive if different centers used different criteria to interpret the results. CDC criterion was found to be very liberal to confirm positive results. There are minimal and no variations found in HIV BLOT 2.2 and genetic systems kits respectively. In genetic systems kit CDC criteria was given to interpret the results. We identified 110 (46.4) of our specimens as positive, 111 (47) as negative and 16 as indeterminate irrespective of criteria used. This results reveals that effect of criteria are nullified with kit with better performance. A detailed record of our findings is presented in [ Table 1 ]. No specific criterion was given by HIV BLOT 2.2 to interpret the results.
Of the 23 specimens that were run on both the LAV BLOT I and the genetic systems kit, we found a lot of discrepancies in the results. Based on the criteria suggested by the manufacturer the LAV BLOT I kit identified 3 specimens as positive, 4 specimens as negative and 16 specimens as indeterminate. However, the genetic systems identified only 2 specimens as positive, 7 specimens as indeterminate but 14 of these 23 specimens as negative. This implies that the LAV BLOT I could be wrongly reporting 10 negative specimens as indeterminate. On further analysis 1 out of this 10 specimens could be read positive if CDC & CRSS criteria were used. This again proves the variations of results with respect to different criteria. Also 1 specimen indeterminate in genetic systems kit was found to be positive in LAV BLOT I kit. We also noticed that the most common band associated with an indeterminate report in the LAV BLOT I kit was the p25 band. Four of the five specimens on which the PCR was performed were reported as negative. The genetic systems kit reported three of these four as negative and one as indeterminate. The other specimen that was reported as positive by the PCR was reported as indeterminate by the genetic systems kit. The LAV BLOT I kit on the other hand reported all the five specimens as indeterminate. Summary of our interkit comparisons are presented in [ Table 2 ]. Six specimens were run on both genetic systems kit and HIV BLOT 2.2, no variations were found in results
DISCUSSION
The results of this study indicate that the choice of best commercially available kit is important than the use of interpretation criteria. It is evident by genetic systems results with uniform number of results on different interpretation criteria. One more key finding noticed that some HIV-1 PCR negative specimens where found to be indeterminate in LAV blot I kit, those where negative in genetic systems kit. Notably an indeterminate specimen was turned out to be positive when read with WHO criterion in LAV BLOT I kit. (7) 16 (7) 16 (7) 16 (7) 16 (7) 16 (7) * gp 120/gp 160 and either (or) both : p24, gp41, † Two env Bands with or without gag or pol ‡ I kit and negative on genetic system kit found to be negative for HIV-1 by PCR. Our reports strongly support earlier studies, [15, 22] that the indeterminate result with p24 itself can not predict early HIV infection, where as some others contradict these findings. [23] The positive or indeterminate Western blot results can affect the patient mantel status, some may often spent many sleepless nights, and some may end up their lives on receiving the report. Hence these results should be interpreted very carefully and the efficient psychosocial posttest counseling is mandatory in VCT centres. Further, HIV-1 negative blood units are discarded as well as the respective donors are resisted from donating blood on the basis of repeated false positive and indeterminate Western blot results, [14, 24, 25] thus the efficiency of kit plays a role in saving discarding true HIV-1 negative blood units.
Further elaborative studies with PCR and immunofluorescence are needed to compare interkit performances. Also we propose that only initially reactive specimen with ELISA or rapid test should be subjected for WB analysis. It is accepted world wide that western blot is a gold standard method for the diagnosis of HIV infection with high specificity. However the one drawback of the WB is the indeterminate result. [1, 6, [9] [10] [11] 15, 24, [26] [27] [28] Measures are needed to restrict indeterminate results only to the patients who are in the window period. A large prospective study is needed with application of different kits and a large specimen size may be helpful to choose superior HIV diagnostic aids.
